Rebound-associated vertebral fractures after denosumab discontinuation in a lung cancer patient with bone metastases

Denosumab is a commonly used antiresorptive treatment in patients with osteoporosis or solid tumours with bone metastases. Upon denosumab discontinuation, a rebound phenomenon can occur that results in an increased (vertebral) fracture risk. This phenomenon is well-known in the setting of osteoporos...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Jolan Dupont, Wesley Appermans, Marian Dejaeger, Isabelle Wauters, Michaël R. Laurent, Evelien Gielen
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Elsevier 2022-06-01
Sarja:Bone Reports
Aiheet:
Bone turnover markers
Denosumab
Osteoporosis
Vertebral fractures
Rebound phenomenon
Linkit:http://www.sciencedirect.com/science/article/pii/S2352187222004168
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia